GlassScriptPhysician profile
Yssra Soliman
NPI 1467913384
$4,070.23
in general payments reported to CMS, 2019-2025
20 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $538 · 2024: $1,995 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,652 · Education: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,652.03 |
| Education | $418.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $700.43 | 2023-2025 | Rinvoq |
| Dermavant Sciences, INC. | $620.89 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $411.38 | 2024-2025 | Tremfya |
| Genzyme Corporation | $334.63 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $289.91 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $272.82 | 2023-2025 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $220.56 | 2025 | Aklief, Nemluvio |
| Ucb, INC. | $213.73 | 2023-2024 | Bimzelx, Cimzia |
| Incyte Corporation | $196.34 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $162.64 | 2023-2025 | |
| Leo Pharma INC. | $147.95 | 2024-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $143.82 | 2023-2024 | Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $136.22 | 2025 | Dupixent, Libtayo |
| Pfizer INC. | $92.76 | 2023-2025 | |
| Organon LLC | $49.98 | 2025 | Vtama |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.05 | 2023 | Arazlo, Duobrii, Jublia |
| Verrica Pharmaceuticals INC. | $15.35 | 2024 | Ycanth |
| Merz North America, INC. | $14.86 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13.90 | 2024 | Sotyktu |
| Biofrontera INC. | $10.01 | 2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yssra Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.